Kailera, Hengrui’s GLP-1/GIP candidate delivers weight, menstrual benefits to women with PMOS
Kailera, Hengrui’s GLP-1/GIP candidate delivers weight, menstrual benefits to women with PMOS
Kailera Therapeutics
Kailera Therapeutics is a clinical-stage biopharmaceutical company developing long-acting peptide therapeutics for obesity and metabolic disease, with a lead asset (ribupatide) targeting GLP-1/GIP dual agonism. The company completed a record-setting IPO in early June 2026 and presented positive Chinese Phase 2 data at the American Diabetes Association conference, positioning it as a notable China-originated obesity biotech in the public markets.
Company Info
Sector:Biotechnology / Metabolic Disease (Peptide Therapeutics)
Headquarters:San Diego, California, USA (with research operations in China)
Founded:2023
Website:www.kailera.com/
Upcoming Milestones & Key Dates
H2 2026
Clinical Trial
Global (ex-China) Phase 2/3 ribupatide obesity development update
Late 2026
Earnings
First post-IPO earnings report and pipeline update
Clinical Development Pipeline
Ribupatide
Target: Long-acting GLP-1 / GIP dual agonist peptideUndisclosed metabolic program
Target: Long-acting peptide platform (targets undisclosed)Undisclosed early-stage programs
Target: Long-acting peptide platform (targets undisclosed)Recent News
ADA: Kailera 'Back at Work' After Record-Breaking IPO With China Data in Hand
Kailera Therapeutics executives said the obesity biotech is back to building pipeline after a record-breaking IPO, presenting Phase 2 data from China on its lead GLP-1/GIP candidate at the American Diabetes Association conference.
Leadership Team
Ronald C. Renaud
Chief Executive Officer